109 related articles for article (PubMed ID: 37057626)
1. Soluble forms of PD-1 and sPD-L1/2 in serum and urine of patients with head and neck cancer and their clinical significance.
Lv Y; Gai K; Ding X; Sun W
Biotechnol Genet Eng Rev; 2023 Apr; ():1-12. PubMed ID: 37057626
[TBL] [Abstract][Full Text] [Related]
2. Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer.
Buderath P; Schwich E; Jensen C; Horn PA; Kimmig R; Kasimir-Bauer S; Rebmann V
Front Oncol; 2019; 9():1015. PubMed ID: 31681568
[No Abstract] [Full Text] [Related]
3. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
[No Abstract] [Full Text] [Related]
4. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
5. Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients.
Vikerfors A; Davidsson S; Frey J; Jerlström T; Carlsson J
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830993
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.
Cheng CL; Yao CY; Huang PH; Yu CW; Fang WQ; Chuang WH; Wu SJ; Lin YJ; Hung YC; Tsai CH; Yu SC; Chou WC; Tien HF
Br J Haematol; 2023 Apr; 201(1):75-85. PubMed ID: 36480431
[TBL] [Abstract][Full Text] [Related]
7. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
8. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Murakami S; Shibaki R; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2020 Dec; 11(12):3585-3595. PubMed ID: 33108686
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity.
Hirahara S; Katsumata Y; Kawasumi H; Kawaguchi Y; Harigai M
Lupus; 2020 Jun; 29(7):686-696. PubMed ID: 32264742
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
[TBL] [Abstract][Full Text] [Related]
11. The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
Zhang X; Lu H; Peng L; Zhou J; Wang M; Li J; Liu Z; Zhang W; Zhao Y; Zeng X; Lu L
Rheumatology (Oxford); 2022 Feb; 61(2):815-825. PubMed ID: 33930105
[TBL] [Abstract][Full Text] [Related]
12. sPD-1 and sPD-L1 Levels in Serum and Urine of Patients with Primary Nephrotic Syndrome and their Clinical Significance.
Xuan Y; Chen F; Qin L; He R; Yuan J
Clin Lab; 2021 Oct; 67(10):. PubMed ID: 34655201
[TBL] [Abstract][Full Text] [Related]
13. sPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance.
Han S; Zhang Y; Yuan J; Wu Y; Zhou Y; Zhou Y; Li X; Zhou S
Cytokine; 2024 Apr; 176():156532. PubMed ID: 38330638
[TBL] [Abstract][Full Text] [Related]
14. Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer.
Aghajani MJ; Roberts TL; Yang T; McCafferty CE; Caixeiro NJ; DeSouza P; Niles N
Endocr Connect; 2019 Jul; 8(7):1040-1051. PubMed ID: 31252406
[TBL] [Abstract][Full Text] [Related]
15. [The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.].
Gershtein ES; Ognerubov NA; Chang VL; Delektorskaya VV; Korotkova EA; Sokolov NY; Polikarpova SB; Stilidi IS; Kushlinskii NE
Klin Lab Diagn; 2020; 65(6):347-352. PubMed ID: 32459892
[TBL] [Abstract][Full Text] [Related]
16. Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab.
Costantini A; Julie C; Dumenil C; Hélias-Rodzewicz Z; Tisserand J; Dumoulin J; Giraud V; Labrune S; Chinet T; Emile JF; Giroux Leprieur E
Oncoimmunology; 2018; 7(8):e1452581. PubMed ID: 30221046
[TBL] [Abstract][Full Text] [Related]
17. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract][Full Text] [Related]
18. Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer.
Sun J; Qiu MZ; Mei T; Gao Y; Chang B; Zhang Y; Wang FH; Li S
Transl Cancer Res; 2020 Apr; 9(4):2434-2448. PubMed ID: 35117603
[TBL] [Abstract][Full Text] [Related]
19. Soluble PD-L1 in blood correlates positively with neutrophil and negatively with lymphocyte mRNA markers and implies adverse sepsis outcome.
Derigs M; Heers H; Lingelbach S; Hofmann R; Hänze J
Immunol Res; 2022 Oct; 70(5):698-707. PubMed ID: 35732880
[TBL] [Abstract][Full Text] [Related]
20. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]